A comparison of the long‐term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study

• Published in: HIV medicine 2011-05, Vol.12 (5), p.259-268
• Main Authors: Reekie, J, Reiss, P, Ledergerber, B, Sedlacek, D, Parczewski, M, Gatell, J, Katlama, C, Fätkenheuer, G, Lundgren, JD, Mocroft, A
• Format: Article
• Language: English
• Subjects: antiviral therapy; Argentina - epidemiology; Benzoxazines - adverse effects; Benzoxazines - therapeutic use; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; durability; Europe - epidemiology; Female; HIV Infections - drug therapy; HIV Infections - epidemiology; HIV Infections - virology; HIV Protease Inhibitors - therapeutic use; HIV-1; Humans; Israel - epidemiology; long‐term adverse events; Lopinavir; Male; Nevirapine - adverse effects; Nevirapine - therapeutic use; Prospective Studies; Pyrimidinones - adverse effects; Pyrimidinones - therapeutic use; Reverse Transcriptase Inhibitors - therapeutic use; Treatment Outcome; Viral Load
• ISSN: 1464-2662; 1468-1293
• DOI: 10.1111/j.1468-1293.2010.00877.x

Objectives The durability of combination antiretroviral therapy (cART) regimens can be measured as time to discontinuation because of toxicity or treatment failure, development of clinical disease or serious long‐term adverse events. The aim of this analysis was to compare the durability of nevirapine, efavirenz and lopinavir regimens based on these measures. Methods Patients starting a nevirapine, efavirenz or lopinavir‐based cART regimen for the first time after 1 January 2000 were included in the analysis. Follow‐up started ≥3 months after initiation of treatment if viral load was